Biotherapy

, Volume 2, Issue 1, pp 21–32 | Cite as

Comparison between crude Interleukin-2 and recombinant Interleukin-2 in maintaining killing activity of cultured lymphocytes

  • Masaki Nakanishi
  • Norimichi Kan
  • Takashi Okino
  • Kohei Satoh
  • Keiichi Mise
  • Yasufumi Teramura
  • Seiji Yamasaki
  • Kazuhisa Ohgaki
  • Takayoshi Tobe
Article

Abstract

Peripheral blood lymphocytes, regional lymph node lymphocytes or malignant effusion lymphocytes from cancer patients were incubated with crude IL-2 (cIL-2) for 13 days. These effectors, which frequently expressed IL-2 receptor (IL-2R), proliferated well and possessed augmented killing activity against fresh autologous tumor cells and K562. However, when recombinant IL-2 (rIL-2) was added for the last 4 days of culture instead of cIL-2, IL-2R expression and killing activity against fresh autologous tumor cells decreased significantly (P<0.05). Phenotypic analysis indicated that cIL-2 significantly promoted the expansion of the cytotoxic population (CD8+ .11b)(P<0.05). The decreases in killing activity and IL-2R expression were restored by 0.004% PHA plus rIL-2, but not in the presence of rIFN-γ, rIL-1α, rIL-lβ, rIL-4 or rIL-6. PHA-free cIL-2 maintained killing activity, but not IL-2R expression.

We conclude that some factors in cIL-2 and a low dose of PHA-P are necessary for the maintenance of killing activity and IL-2R expression of cultured lymphocytes in the late phase of culture.

Key words

crude Interleukin-2 recombinant Interleukin-2 killing activity IL-2 receptor expression 

Abbreviations

α

anti

cIL-2

crude IL-2

cmp

counts/min

CTL

cytotoxic T lymphocytes

IL-2R

IL-2 receptor

JU

Jurkat Unit

LAK

lymphokine activated killer

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grimm EA, Mazumder A, Zhang HT, Rosenberg SA. 1982. Lymphokine-activated killer cell phenomenon: Lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823.PubMedGoogle Scholar
  2. 2.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889.PubMedGoogle Scholar
  3. 3.
    Itoh K, Tilden AB, Balch CB. 1986. Interleukin-2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res. 46: 3011.PubMedGoogle Scholar
  4. 4.
    Syu S, Chou T, Rosenberg SA. 1986.In vitro sensitization and expansion with viable tumor cells and interleukin-2 in the generation of specific therapeutic effector cells. J Immunol 136 (10): 3891.PubMedGoogle Scholar
  5. 5.
    Ochoa AC, Gromo G, Alter BJ. 1987. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3,β-IL1, interferon-γ and -β. J Immunol 138 (8): 2728.PubMedGoogle Scholar
  6. 6.
    Kimoto Y, Tanji Y, Fujiwara A, Tanaka T, Taguchi T. 1988. Effect of anti-T3 (CD3) monoclonal antibody OKT3 on the proliferation of LAK cells and cytotoxicity. Biotherapy (Japan) 2 (2): 380.Google Scholar
  7. 7.
    Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41: 4420.PubMedGoogle Scholar
  8. 8.
    Hori T, Kan N, Yamasaki N, Nio Y, Ohgaki K, Tobe T. 1985. The cytotoxic activity of tumor infiltrating lymphocytes (TIL) and its application for adoptive immunotherapy. J Jpn Soc Cancer Ther 20: 943.Google Scholar
  9. 9.
    Hori T, Kan N, Nio Y, Tsuchitani T, Inamoto T, Kodama H, Tobe T. 1986. Augmentation by OK-432 of cytotoxic activities of lymphocytes in carcinomatous pleural effusions and its application for adoptive immunotherapy. In new application of OK-432. T. Tobe, eds. Excerpta Medica, Tokyo, Japan, 132.Google Scholar
  10. 10.
    Kan N, Ohgaki K, Yamasaki N, Hori T, Nakayama N, Nio Y, Inamoto T, Hikasa Y. 1983b. Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: A clinical trial. Arch Jpn Chir 52: 841.Google Scholar
  11. 11.
    Kan N, Ohgaki K, Inamoto T, Kodama H. 1984. Anti-tumor and therapeutic effects of spleen cells from tumorbearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immnother 18: 215.Google Scholar
  12. 12.
    Gillis S, Ferm MM, On W, Smith KA. 1978. T cell growth factor; parameters of production and a quantitative microassay for activity. J Immunol 120: 2027.PubMedGoogle Scholar
  13. 13.
    Ohno T, Kanoh T, Suzuki T, Masuda T, Kuribayashi K, Araya S, Arai H, Uchino H. 1988. Comparative analysis of lymphocyte phenotype between carrier of human immunodeficiency virus (HIV) and adult patients with primary immunodeficiency using two-color immunofluorescence Flow-cytometry. Tohoku J Exp Med 154: 157.PubMedGoogle Scholar
  14. 14.
    Falk W, Mannel DA, Droge W. 1983. Activation of cytotoxic lymphocytes requires at least two spleen cell-derived helper factors besides interleukin 2. J Immunol 130: 2214.PubMedGoogle Scholar
  15. 15.
    Yang SS, Malek TR, Hargrove ME, Ting C. 1985. Lymphokine-induced cytotoxicity: Requirement of two lymphokines for the induction of optimal cytotoxic responses. J Immunol 134: 3912.PubMedGoogle Scholar
  16. 16.
    Garman RD, Fan DP. 1983. Characterization of helper factors distinct from interleukin 2 necessary for the generation of allospecific cytolytic T lymphocyte. J Immunol 130: 756.PubMedGoogle Scholar
  17. 17.
    Finke JH, Scott J, Gillis S, Hilfiker ML. 1983. Generation of alloreactive cytotoxic T lymphocytes: Evidence for a differentiation factor distinct from IL2. J Immunol 130: 763.PubMedGoogle Scholar
  18. 18.
    Lindhal P, Leary P, Gresser I. 1972. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 69: 721.PubMedGoogle Scholar
  19. 19.
    Heron R, Berg K, Cantell K. 1976. Regulatory effects of interferon on T cell in vitro. J Immunol 117: 1370.PubMedGoogle Scholar
  20. 20.
    Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K. 1985. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL-2) in collaboration with interferon-γ (IFN-γ). J Immunol 134: 3124.PubMedGoogle Scholar
  21. 21.
    Spits H, Yssel H, Takebe Y, Arai N, Yokota T, Lee F, Arai K, Banchereau J, Vries J. 1987. Recombinant interleukin 4 promotes the growth of human T cells. J Immunol 139: 1142.PubMedGoogle Scholar
  22. 22.
    Widmer MB, Grabstein KH. 1987. Regulation of cytolytic T lymphocyte generation by B-cell stimulatory factor. Nature 326: 795.PubMedGoogle Scholar
  23. 23.
    Okada M, Takahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. 1988. IL6/BSF-2 functions as killer helper factor in the induction of cytotoxic T cells. J Immunol 141: 1543.PubMedGoogle Scholar
  24. 24.
    Takatsu K, Kikuchi Y, Takahashi T, Honjo T, Matsumoto M, Harada N, Yamaguchi N, Tominaga A. 1987. Interleukin 5, a T-cell-derived B-cell differentiation factor also induced cytotoxic T lymphocyte. Immunol 84: 4234.Google Scholar
  25. 25.
    Mazumder A, Grimm EA, Zhang HZ, Rosenberg SA. 1982. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res. 42: 913.PubMedGoogle Scholar
  26. 26.
    Roifman CM, Mills GB, Chu M, Gelfand EW. 1985. Functional comparison of recombinant interleukin 2 (IL2) with IL-2-containing preparations derived from cultured cells. Cell Immunol 95: 146.PubMedGoogle Scholar
  27. 27.
    Doyle MV, Lee MT, Fong S. 1985. Comparison of the biological activities of human recombinant interleukin-2125 and native interleukin-2. J Biol Resp Modif 4 (1): 96.Google Scholar
  28. 28.
    Kaye J, Gillis S, Mizel SB, Shevach LB, Charles A, Janeway JR. 1984. Growth of a clonal helper T ell line induced by a monoclonal antibody specific for the antigen receptor: Interleukin 1 is required for the expression of receptor for interleukin 2. J Immunol 133: 1339.PubMedGoogle Scholar
  29. 29.
    Matis LA, Shu S, Groves ES, Zinn S, Chou T, Kruisbeek AM, Rosenstein M, Rosenberg SA. 1986. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL-2 receptor expression. J Immunol 136: 3496.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Masaki Nakanishi
    • 1
  • Norimichi Kan
    • 1
  • Takashi Okino
    • 1
  • Kohei Satoh
    • 1
  • Keiichi Mise
    • 1
  • Yasufumi Teramura
    • 1
  • Seiji Yamasaki
    • 1
  • Kazuhisa Ohgaki
    • 1
  • Takayoshi Tobe
    • 1
  1. 1.Laboratory of Oncologic Surgery, First Department of SurgerySchool of Medicine Kyoto UniversityKyotoJapan

Personalised recommendations